Cargando…

Landiolol for the prevention of postoperative atrial fibrillation after cardiac surgery: a systematic review and meta-analysis

PURPOSE: Postoperative atrial fibrillation (POAF) is a common complication following cardiac surgery. Although the evidence suggests that beta blockers prevent POAF, they often cause hypotension. Landiolol, an ultra-short-acting β(1) blocker, may prevent POAF, without adverse hemodynamic consequence...

Descripción completa

Detalles Bibliográficos
Autores principales: Cafaro, Teresa, Allwood, Melissa, McIntyre, William F., Park, Lily J., Daza, Julian, Ofori, Sandra N., Ke Wang, Michael, Borges, Flavia K., Conen, David, Marcucci, Maura, Healey, Jeff S., Whitlock, Richard P., Lamy, Andre, Belley-Côté, Emilie P., Spence, Jessica D., McGillion, Michael, Devereaux, P. J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10656308/
https://www.ncbi.nlm.nih.gov/pubmed/37917331
http://dx.doi.org/10.1007/s12630-023-02586-0
_version_ 1785136985264881664
author Cafaro, Teresa
Allwood, Melissa
McIntyre, William F.
Park, Lily J.
Daza, Julian
Ofori, Sandra N.
Ke Wang, Michael
Borges, Flavia K.
Conen, David
Marcucci, Maura
Healey, Jeff S.
Whitlock, Richard P.
Lamy, Andre
Belley-Côté, Emilie P.
Spence, Jessica D.
McGillion, Michael
Devereaux, P. J.
author_facet Cafaro, Teresa
Allwood, Melissa
McIntyre, William F.
Park, Lily J.
Daza, Julian
Ofori, Sandra N.
Ke Wang, Michael
Borges, Flavia K.
Conen, David
Marcucci, Maura
Healey, Jeff S.
Whitlock, Richard P.
Lamy, Andre
Belley-Côté, Emilie P.
Spence, Jessica D.
McGillion, Michael
Devereaux, P. J.
author_sort Cafaro, Teresa
collection PubMed
description PURPOSE: Postoperative atrial fibrillation (POAF) is a common complication following cardiac surgery. Although the evidence suggests that beta blockers prevent POAF, they often cause hypotension. Landiolol, an ultra-short-acting β(1) blocker, may prevent POAF, without adverse hemodynamic consequences. SOURCE: We searched MEDLINE, CENTRAL, Embase, and trial registries between January 1970 and March 2022. We included randomized controlled trials (RCTs) that evaluated the effect of landiolol for the prevention of POAF after cardiac surgery. Two reviewers independently assessed eligibility, extracted data, and assessed risk of bias using the Risk of Bias 2.0 tool. We pooled data using random-effects models. We used the Grading of Recommendations, Assessment, Development and Evaluations framework to assess certainty of evidence. PRINCIPAL FINDINGS: Nine RCTs including 868 participants met the eligibility criteria. Patients randomized to landiolol (56/460) had less POAF compared with controls (133/408) with a relative risk (RR) of 0.40 (95% confidence interval [CI], 0.30 to 0.54; I(2) = 0%;) and an absolute risk of 12.2% vs 32.6% (absolute risk difference, 20.4%; 95% CI, 15.0 to 25.0). Landiolol resulted in a shorter hospital length-of-stay (LOS) (268 patients; mean difference, −2.32 days; 95% CI, −4.02 to −0.57; I(2) = 0%). We found no significant difference in bradycardia (RR, 1.11; 95% CI, 0.48 to 2.56; I(2) = 0%). No hypotension was reported with landiolol. We judged the certainty of evidence as moderate for POAF (because of indirectness as outcomes were not clearly defined) and low for LOS (because of imprecision and concern of reporting bias). CONCLUSION: In patients undergoing cardiac surgery, landiolol likely reduces POAF and may reduce LOS. A definitive large RCT is needed to confirm these findings. STUDY REGISTRATION: PROSPERO (CRD42021262703); registered 25 July 2021. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12630-023-02586-0.
format Online
Article
Text
id pubmed-10656308
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-106563082023-11-02 Landiolol for the prevention of postoperative atrial fibrillation after cardiac surgery: a systematic review and meta-analysis Cafaro, Teresa Allwood, Melissa McIntyre, William F. Park, Lily J. Daza, Julian Ofori, Sandra N. Ke Wang, Michael Borges, Flavia K. Conen, David Marcucci, Maura Healey, Jeff S. Whitlock, Richard P. Lamy, Andre Belley-Côté, Emilie P. Spence, Jessica D. McGillion, Michael Devereaux, P. J. Can J Anaesth Review Article/Brief Review PURPOSE: Postoperative atrial fibrillation (POAF) is a common complication following cardiac surgery. Although the evidence suggests that beta blockers prevent POAF, they often cause hypotension. Landiolol, an ultra-short-acting β(1) blocker, may prevent POAF, without adverse hemodynamic consequences. SOURCE: We searched MEDLINE, CENTRAL, Embase, and trial registries between January 1970 and March 2022. We included randomized controlled trials (RCTs) that evaluated the effect of landiolol for the prevention of POAF after cardiac surgery. Two reviewers independently assessed eligibility, extracted data, and assessed risk of bias using the Risk of Bias 2.0 tool. We pooled data using random-effects models. We used the Grading of Recommendations, Assessment, Development and Evaluations framework to assess certainty of evidence. PRINCIPAL FINDINGS: Nine RCTs including 868 participants met the eligibility criteria. Patients randomized to landiolol (56/460) had less POAF compared with controls (133/408) with a relative risk (RR) of 0.40 (95% confidence interval [CI], 0.30 to 0.54; I(2) = 0%;) and an absolute risk of 12.2% vs 32.6% (absolute risk difference, 20.4%; 95% CI, 15.0 to 25.0). Landiolol resulted in a shorter hospital length-of-stay (LOS) (268 patients; mean difference, −2.32 days; 95% CI, −4.02 to −0.57; I(2) = 0%). We found no significant difference in bradycardia (RR, 1.11; 95% CI, 0.48 to 2.56; I(2) = 0%). No hypotension was reported with landiolol. We judged the certainty of evidence as moderate for POAF (because of indirectness as outcomes were not clearly defined) and low for LOS (because of imprecision and concern of reporting bias). CONCLUSION: In patients undergoing cardiac surgery, landiolol likely reduces POAF and may reduce LOS. A definitive large RCT is needed to confirm these findings. STUDY REGISTRATION: PROSPERO (CRD42021262703); registered 25 July 2021. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12630-023-02586-0. Springer International Publishing 2023-11-02 2023 /pmc/articles/PMC10656308/ /pubmed/37917331 http://dx.doi.org/10.1007/s12630-023-02586-0 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by-nc/4.0/Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Review Article/Brief Review
Cafaro, Teresa
Allwood, Melissa
McIntyre, William F.
Park, Lily J.
Daza, Julian
Ofori, Sandra N.
Ke Wang, Michael
Borges, Flavia K.
Conen, David
Marcucci, Maura
Healey, Jeff S.
Whitlock, Richard P.
Lamy, Andre
Belley-Côté, Emilie P.
Spence, Jessica D.
McGillion, Michael
Devereaux, P. J.
Landiolol for the prevention of postoperative atrial fibrillation after cardiac surgery: a systematic review and meta-analysis
title Landiolol for the prevention of postoperative atrial fibrillation after cardiac surgery: a systematic review and meta-analysis
title_full Landiolol for the prevention of postoperative atrial fibrillation after cardiac surgery: a systematic review and meta-analysis
title_fullStr Landiolol for the prevention of postoperative atrial fibrillation after cardiac surgery: a systematic review and meta-analysis
title_full_unstemmed Landiolol for the prevention of postoperative atrial fibrillation after cardiac surgery: a systematic review and meta-analysis
title_short Landiolol for the prevention of postoperative atrial fibrillation after cardiac surgery: a systematic review and meta-analysis
title_sort landiolol for the prevention of postoperative atrial fibrillation after cardiac surgery: a systematic review and meta-analysis
topic Review Article/Brief Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10656308/
https://www.ncbi.nlm.nih.gov/pubmed/37917331
http://dx.doi.org/10.1007/s12630-023-02586-0
work_keys_str_mv AT cafaroteresa landiololforthepreventionofpostoperativeatrialfibrillationaftercardiacsurgeryasystematicreviewandmetaanalysis
AT allwoodmelissa landiololforthepreventionofpostoperativeatrialfibrillationaftercardiacsurgeryasystematicreviewandmetaanalysis
AT mcintyrewilliamf landiololforthepreventionofpostoperativeatrialfibrillationaftercardiacsurgeryasystematicreviewandmetaanalysis
AT parklilyj landiololforthepreventionofpostoperativeatrialfibrillationaftercardiacsurgeryasystematicreviewandmetaanalysis
AT dazajulian landiololforthepreventionofpostoperativeatrialfibrillationaftercardiacsurgeryasystematicreviewandmetaanalysis
AT oforisandran landiololforthepreventionofpostoperativeatrialfibrillationaftercardiacsurgeryasystematicreviewandmetaanalysis
AT kewangmichael landiololforthepreventionofpostoperativeatrialfibrillationaftercardiacsurgeryasystematicreviewandmetaanalysis
AT borgesflaviak landiololforthepreventionofpostoperativeatrialfibrillationaftercardiacsurgeryasystematicreviewandmetaanalysis
AT conendavid landiololforthepreventionofpostoperativeatrialfibrillationaftercardiacsurgeryasystematicreviewandmetaanalysis
AT marcuccimaura landiololforthepreventionofpostoperativeatrialfibrillationaftercardiacsurgeryasystematicreviewandmetaanalysis
AT healeyjeffs landiololforthepreventionofpostoperativeatrialfibrillationaftercardiacsurgeryasystematicreviewandmetaanalysis
AT whitlockrichardp landiololforthepreventionofpostoperativeatrialfibrillationaftercardiacsurgeryasystematicreviewandmetaanalysis
AT lamyandre landiololforthepreventionofpostoperativeatrialfibrillationaftercardiacsurgeryasystematicreviewandmetaanalysis
AT belleycoteemiliep landiololforthepreventionofpostoperativeatrialfibrillationaftercardiacsurgeryasystematicreviewandmetaanalysis
AT spencejessicad landiololforthepreventionofpostoperativeatrialfibrillationaftercardiacsurgeryasystematicreviewandmetaanalysis
AT mcgillionmichael landiololforthepreventionofpostoperativeatrialfibrillationaftercardiacsurgeryasystematicreviewandmetaanalysis
AT devereauxpj landiololforthepreventionofpostoperativeatrialfibrillationaftercardiacsurgeryasystematicreviewandmetaanalysis